Is HALO or PXS more profitable?

HaloSource has a net margin of 0.00% compared to Provexis' net margin of -69.30%. HaloSource's return on equity of 0.00% beat Provexis' return on equity. Company Net Margins Return on Equity Return on Assets HaloSource N/A N/A N/A Provexis -69.30% -49.45% -56.14%

Is MXC or HALO more profitable?

Company Net Margins Return on Equity Return on Assets Argent BioPharma N/A N/A -58.96% HaloSource N/A N/A N/A

Does the media refer more to MXC or HALO?

In the previous week, Argent BioPharma and Argent BioPharma both had 1 articles in the media. HaloSource's average media sentiment score of 0.00 beat Argent BioPharma's score of -0.35 indicating that HaloSource is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Argent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral HaloSource 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, HALO or RGT?

HaloSource is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HaloSource N/A N/A N/A -£1.49 N/A Argent BioPharma N/A N/A -£17.53M -£0.24 N/A

Which has preferable earnings and valuation, HALO or IDP?

HaloSource is trading at a lower price-to-earnings ratio than InnovaDerma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HaloSource N/A N/A N/A -£1.49 N/A InnovaDerma £9.82M 0.00 N/A -£7.50 N/A

Is HALO or IDP more profitable?

Company Net Margins Return on Equity Return on Assets HaloSource N/A N/A N/A InnovaDerma N/A N/A N/A

HaloSource (HALO) Competitors

GBX 9.45 0.00 (0.00%)

As of 07/31/2026 12:01 PM Eastern

Compare

HALO vs. PXS, MXC, RGT, CEL, and IDP

Should you buy HaloSource stock or one of its competitors? MarketBeat compares HaloSource with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HaloSource include Provexis (PXS), Argent BioPharma (MXC), Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), and InnovaDerma (IDP). These companies are all part of the "pharmaceuticals" industry.

How does HaloSource compare to Provexis?

HaloSource (LON:HALO) and Provexis (LON:PXS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

HaloSource has a net margin of 0.00% compared to Provexis' net margin of -69.30%. HaloSource's return on equity of 0.00% beat Provexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HaloSource	N/A	N/A	N/A
Provexis	-69.30%	-49.45%	-56.14%

7.9% of Provexis shares are owned by institutional investors. 11.8% of Provexis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, HaloSource had 1 more articles in the media than Provexis. MarketBeat recorded 1 mentions for HaloSource and 0 mentions for Provexis. HaloSource's average media sentiment score of 0.00 equaled Provexis'average media sentiment score.

Company	Overall Sentiment
HaloSource	Neutral
Provexis	Neutral

HaloSource has higher earnings, but lower revenue than Provexis. Provexis is trading at a lower price-to-earnings ratio than HaloSource, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HaloSource	N/A	N/A	N/A	-£1.49	N/A
Provexis	£871.27K	32.63	-£619.15K	-£0.02	N/A

Summary

HaloSource beats Provexis on 5 of the 9 factors compared between the two stocks.

How does HaloSource compare to Argent BioPharma?

Argent BioPharma (LON:MXC) and HaloSource (LON:HALO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

1.2% of Argent BioPharma shares are held by institutional investors. 8.2% of Argent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Argent BioPharma and Argent BioPharma both had 1 articles in the media. HaloSource's average media sentiment score of 0.00 beat Argent BioPharma's score of -0.35 indicating that HaloSource is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Argent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
HaloSource	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HaloSource has lower revenue, but higher earnings than Argent BioPharma. HaloSource is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Argent BioPharma	£1.32M	0.00	-£17.02M	-£1.66	N/A
HaloSource	N/A	N/A	N/A	-£1.49	N/A

Company	Net Margins	Return on Equity	Return on Assets
Argent BioPharma	N/A	N/A	-58.96%
HaloSource	N/A	N/A	N/A

Summary

HaloSource beats Argent BioPharma on 4 of the 7 factors compared between the two stocks.

How does HaloSource compare to Argent BioPharma?

HaloSource (LON:HALO) and Argent BioPharma (LON:RGT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

HaloSource is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HaloSource	N/A	N/A	N/A	-£1.49	N/A
Argent BioPharma	N/A	N/A	-£17.53M	-£0.24	N/A

HaloSource has a net margin of 0.00% compared to Argent BioPharma's net margin of -1,967.38%. Argent BioPharma's return on equity of 279.26% beat HaloSource's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HaloSource	N/A	N/A	N/A
Argent BioPharma	-1,967.38%	279.26%	-108.57%

1.1% of Argent BioPharma shares are owned by institutional investors. 17.8% of Argent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, HaloSource had 1 more articles in the media than Argent BioPharma. MarketBeat recorded 1 mentions for HaloSource and 0 mentions for Argent BioPharma. HaloSource's average media sentiment score of 0.00 equaled Argent BioPharma'saverage media sentiment score.

Company	Overall Sentiment
HaloSource	Neutral
Argent BioPharma	Neutral

Summary

Argent BioPharma beats HaloSource on 5 of the 8 factors compared between the two stocks.

How does HaloSource compare to Celadon Pharmaceuticals?

Celadon Pharmaceuticals (LON:CEL) and HaloSource (LON:HALO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

HaloSource has lower revenue, but higher earnings than Celadon Pharmaceuticals. HaloSource is trading at a lower price-to-earnings ratio than Celadon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celadon Pharmaceuticals	£123.38K	66.61	-£4.97M	-£7.98	N/A
HaloSource	N/A	N/A	N/A	-£1.49	N/A

10.7% of Celadon Pharmaceuticals shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

HaloSource has a net margin of 0.00% compared to Celadon Pharmaceuticals' net margin of -9,520.00%. HaloSource's return on equity of 0.00% beat Celadon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celadon Pharmaceuticals	-9,520.00%	-131.82%	-34.40%
HaloSource	N/A	N/A	N/A

In the previous week, HaloSource had 1 more articles in the media than Celadon Pharmaceuticals. MarketBeat recorded 1 mentions for HaloSource and 0 mentions for Celadon Pharmaceuticals. Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled HaloSource'saverage media sentiment score.

Company	Overall Sentiment
Celadon Pharmaceuticals	Neutral
HaloSource	Neutral

Summary

HaloSource beats Celadon Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does HaloSource compare to InnovaDerma?

HaloSource (LON:HALO) and InnovaDerma (LON:IDP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

HaloSource is trading at a lower price-to-earnings ratio than InnovaDerma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HaloSource	N/A	N/A	N/A	-£1.49	N/A
InnovaDerma	£9.82M	0.00	N/A	-£7.50	N/A

Company	Net Margins	Return on Equity	Return on Assets
HaloSource	N/A	N/A	N/A
InnovaDerma	N/A	N/A	N/A

In the previous week, HaloSource had 1 more articles in the media than InnovaDerma. MarketBeat recorded 1 mentions for HaloSource and 0 mentions for InnovaDerma. HaloSource's average media sentiment score of 0.00 equaled InnovaDerma'saverage media sentiment score.

Company	Overall Sentiment
HaloSource	Neutral
InnovaDerma	Neutral

Summary

HaloSource and InnovaDerma tied by winning 2 of the 4 factors compared between the two stocks.

Get HaloSource News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HALO vs. The Competition

Export

Metric	HaloSource	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£10.47M	£11.74B	£6.86B	£2.82B
Dividend Yield	N/A	2.73%	2.59%	6.15%
P/E Ratio	-6.34	799.05	282.27	368.29
Price / Sales	N/A	749.34	590.91	83,501.30
Price / Cash	N/A	14.82	28.60	27.89
Price / Book	N/A	10.39	10.93	7.04
Net Income	N/A	£2.82B	£3.49B	£5.89B
7 Day Performance	-6.32%	-0.18%	-0.64%	6.05%
1 Month Performance	-2.44%	-4.04%	-3.78%	-0.22%
1 Year Performance	N/A	156.15%	61.99%	63.72%

HaloSource Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HALO HaloSource	N/A	GBX 9.45 flat	N/A	N/A	£10.47M	N/A	N/A	390	Gap Up
PXS Provexis	N/A	GBX 1.21 +6.3%	N/A	+66.5%	£28.43M	£871.27K	N/A	4	Gap Down
MXC Argent BioPharma	N/A	N/A	N/A	N/A	£9.65M	£1.32M	N/A	5	Gap Up
RGT Argent BioPharma	N/A	N/A	N/A	N/A	£8.31M	N/A	N/A	N/A	Gap Down High Trading Volume
CEL Celadon Pharmaceuticals	N/A	GBX 13.40 flat	N/A	N/A	£8.22M	£123.38K	N/A	2,780

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HALO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HaloSource (HALO) Competitors

HALO vs. PXS, MXC, RGT, CEL, and IDP

How does HaloSource compare to Provexis?

Summary

How does HaloSource compare to Argent BioPharma?

Summary

How does HaloSource compare to Argent BioPharma?

Summary

How does HaloSource compare to Celadon Pharmaceuticals?

Summary

How does HaloSource compare to InnovaDerma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

HaloSource Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HaloSource (HALO) Competitors

HALO vs. PXS, MXC, RGT, CEL, and IDP

How does HaloSource compare to Provexis?

Is HALO or PXS more profitable?

Do institutionals & insiders hold more shares of HALO or PXS?

Does the media prefer HALO or PXS?

Which has preferable earnings and valuation, HALO or PXS?

Summary

How does HaloSource compare to Argent BioPharma?

Do insiders & institutionals hold more shares of MXC or HALO?

Does the media refer more to MXC or HALO?

Which has higher earnings & valuation, MXC or HALO?

Is MXC or HALO more profitable?

Summary

How does HaloSource compare to Argent BioPharma?

Which has preferable earnings & valuation, HALO or RGT?

Is HALO or RGT more profitable?

Do institutionals and insiders believe in HALO or RGT?

Does the media refer more to HALO or RGT?

Summary

How does HaloSource compare to Celadon Pharmaceuticals?

Which has preferable earnings & valuation, CEL or HALO?

Do insiders and institutionals have more ownership in CEL or HALO?

Is CEL or HALO more profitable?

Does the media favor CEL or HALO?

Summary

How does HaloSource compare to InnovaDerma?

Which has preferable earnings and valuation, HALO or IDP?

Is HALO or IDP more profitable?

Does the media prefer HALO or IDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

HaloSource Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools